# The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients.

> **NCT04450953** · PHASE3 · RECRUITING · sponsor: **Central Hospital, Nancy, France** · enrollment: 36 (estimated)

## Conditions studied

- Kidney Transplantation for More Than One Year
- Patients with a Kidney Transplantation on Cyclosporine

## Interventions

- **DRUG:** Eplerenone 50mg/day (cross over design)
- **OTHER:** Period without eplerenone (cross over design)

## Key facts

- **NCT ID:** NCT04450953
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-12
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04450953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04450953, "The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04450953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*